LightOx is headquartered in Newcastle upon Tyne, UK and is developing new light activated drug compounds. We are targeting a treatment for early stage and pre-cancerous lesions and are currently completing pre-clinical testing. Our lead candidate will enter Phase I/IIa study for the treatment of early-stage oral cancer lesions in 2025 with our clinical team in Liverpool, UK. With an IP portfolio consisting of five global patents, and a vibrant team experienced in the development of novel therapeutics, LightOx has a solid scientific and commercial base and looks to create a range of treatments from its platform technology. We are exploring projects and applications that spread beyond oncology targets, with the technology demonstrated in bacterial, fungal and plant species.